Zhejiang Medicine (600216.SH): ARX305 initiates Phase II clinical trial.
Zhejiang Medicine (600216.SH) announced that its subsidiary Zhejiang Xinma Biopharmaceutical Co., Ltd. ("Xinma Biopharma") has initiated a single-arm, open-label phase II clinical study to evaluate the efficacy and safety of injectable recombinant humanized anti-CD70 monoclonal antibody-AS269 (ARX305) in relapsed/refractory lymphomas.
Zhejiang Medicine (600216.SH) announced that its subsidiary Zhejiang Xinma Biological Medicine Co., Ltd. (referred to as "Xinma Biological") has initiated a Phase II clinical study to evaluate the efficacy and safety of ARX305, a recombinant humanized anti-CD70 monoclonal antibody-AS269 conjugate for the treatment of relapsed/refractory lymphoma.
The announcement stated that ARX305 was developed through a collaboration agreement signed on October 22, 2019 between Xinma Biological and Ambrx, a company based in the United States. ARX305 is a next-generation monoclonal antibody conjugate drug for the treatment of late-stage tumors expressing CD70, classified as an innovative biotechnology drug.
Related Articles
ANDRE JUICE (02218): Li Yufeng has been appointed to replace Yu Haifeng as the signing registered accountant.
SIIC Environment (00807) will distribute a final dividend of 0.011 Singapore dollars per share on May 29th.
Shenwan Hongyuan Group (06806): "22 Shen Hong 02" will pay interest on March 9th.
ANDRE JUICE (02218): Li Yufeng has been appointed to replace Yu Haifeng as the signing registered accountant.
SIIC Environment (00807) will distribute a final dividend of 0.011 Singapore dollars per share on May 29th.
Shenwan Hongyuan Group (06806): "22 Shen Hong 02" will pay interest on March 9th.
RECOMMEND
